Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity  Starpharma Holdings Limited					
Starpharma Holdings Ellinted					
ABN					
20 078 532 180					
We (the entity) give ASX the fo	ollowing information				
We (the entity) give ASX the following information.					

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- (i) Ordinary Shares
- (ii) Employee Performance Rights (SPLAK) in respect of ordinary shares issued under the rules of the Starpharma Employee Performance Rights Plan.
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- (i) 25,888 Ordinary Shares
- (ii) 50,000 Employee Performance Rights

Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

- 3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- (i) Ordinary fully paid shares issued under the Starpharma Holdings Limited Employee Share Plan.
- (ii) Performance Rights issued under the Starpharma Holdings Ltd Employee Performance Rights Plan (Rights Plan), with a vesting date of 15 January 2015, subject to satisfaction of certain vesting conditions (there may be early vesting if certain events occur). Within 10 Business Days after vesting, one ordinary fully paid share will be issued for each vested Right. Shares issued upon vesting of the Rights will be escrowed until 15 January 2016 provided that the shares may be released early in accordance with the Rules of the Rights Plan.
- 4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- (i) Yes
- (ii) The shares to be issued as a result of vesting of the Employee Performance Rights will rank equally with existing ordinary fully paid shares from the vesting date.

5 Issue price or consideration

Nil

- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- (i) Eligible employees were each invited to apply for 809 ordinary shares, being the nearest number of whole shares to the value of \$1,000 (rounded down) based on the closing price of the shares on the day prior to the offer (\$1.235).
- (ii) To incentivise and retain key employees.
- 7 Dates of entering \*securities into uncertificated holdings or despatch of certificates

18 January 2013

<sup>+</sup> See chapter 19 for defined terms.

8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
283,665,948	Ordinary shares
	-

<sup>+</sup> See chapter 19 for defined terms.

Number +Class 9 Number and +class of all 784,000 Options expiring at +securities not quoted on ASX various dates ex (including the securities in clause various prices 2 if applicable) (SPLAM) 2,082,400 Last notice Lapsed since last (9,000)notice Lapsing 18/01/2013 (90,000)This notice 50,000 Performance Rights 2,033,400 (SPLAK) 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) Part 2 - Bonus issue or pro rata issue 11 Is security holder approval required? 12 Is the issue renounceable or nonrenounceable? Ratio in which the +securities will be offered 14 +Class of +securities to which the offer relates 15 +Record date determine entitlements Will holdings on different registers 16 (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions 18 Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 19 Closing date for receipt of acceptances or renunciations

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders
25	If the issue is contingent on   †security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do *security holders sell their entitlements in full through a broker?
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do *security holders dispose ir entitlements (except by sale th a broker)?		
33	+Desp	atch date		
		Quotation of secur		
34	Type of	of securities <i>ne</i> )		
(a)		Securities described in Part 1 (	i)	
(b)			of the escrowed period, partly paid securities that become fully paid, employee nds, securities issued on expiry or conversion of convertible securities	
Entities that have ticked box 34(a)				
Additi	onal se	curities forming a new class	of securities	
Tick to docume		you are providing the informat	ion or	
35			securities, the names of the 20 largest holders of the number and percentage of additional *securities held by	
36		If the +securities are +equity +securities setting out the num 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	securities, a distribution schedule of the additional per of holders in the categories	
37		A copy of any trust deed for the	e additional +securities	

<sup>+</sup> See chapter 19 for defined terms.

Entities that have ticked box 34(b)					
38	Number of securities for which <sup>+</sup> quotation is sought				
39	Class of *securities for which quotation is sought				
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?				
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment				
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of				
	another security, clearly identify that other security)				
		Number	+Class		
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	Tunibu	CIUSS		

## **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

<sup>+</sup> See chapter 19 for defined terms.

- There is no reason why those \*securities should not be granted \*quotation.
- An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information 4 or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 17 January, 2013 .....

Company Secretary

Print name: B P Rogers

== == == ==

<sup>+</sup> See chapter 19 for defined terms.